Boiko V. Clinical and pathogenetic and genetic aspects of the substantiation of metabolic disorders and optimization of their correction in arterial hypertension in combination ischemic heart disease and type 2 diabetes.

The dissertation presents the generalization of the results of the complex study of the features of carbohydrate and lipid metabolism, prooxidant and antioxidant systems, content of NO end-metabolites, VEGF-A endothelial vascular growth factor, polymorphism of the gene ?-receptor activating peroxisomal proliferation in the blood of patients with hypertension combined with ischemic heart disease and type 2 diabetes mellitus (DM 2) and solves the problem of practical medicine - to improve treatment by correcting metabolic factors of cardiovascular risk using antioxidants and NO donators. The expediency of adding to the basic treatment of patients of quercetin and arginine hydrochloride, that positively affect carbohydrate and lipid metabolism, reduce lipid peroxidation, improve antioxidant protection, help to increase the content of end metabolites NO of blood and endothelial vascular growth factor VEGF-A, has been proven. The dynamics of metabolic rates due to metabolic therapy is more significant in patients with arterial hypertension stage 2 in combination with stable ischemic heart disease with genotype Pro / Ala gene PPAR?2.